From Insights to Action: Key Takeaways and Final Conclusions on Intranasal Epinephrine
July 7th 2025A panelist emphasizes that shared decision-making in anaphylaxis management is essential, combining evidence-based guidelines with individual patient circumstances and preferences—especially regarding newer options like intranasal epinephrine—to ensure timely, confident use while addressing practical concerns, such as access, cost, and education.
Real-World Impact: Patient Cases of Anaphylaxis and Intranasal Epinephrine
July 7th 2025A panelist highlights how neffy, a needle-free, portable intranasal epinephrine device, addresses key unmet needs by reducing needle anxiety, enabling easy use by nonmedical caregivers, offering longer shelf life and temperature stability, and improving timely administration to prevent severe anaphylaxis outcomes, as demonstrated in clinical case examples.
The Clinical Safety and Practical Advantages to Intranasal Epinephrine
July 7th 2025A panelist discusses that the intranasal epinephrine device causes only mild, expected adverse effects such as nasal discomfort and headache, avoids injection-related risks, demonstrates rapid symptom improvement in pediatric food challenge studies, and offers practical advantages such as higher heat tolerance for storage and a longer shelf life compared with traditional autoinjectors.
Advancing Anaphylaxis Treatment: The Science Behind Intranasal Epinephrine
July 7th 2025A panelist discusses a newly approved intranasal epinephrine device for treating anaphylaxis in both children and adults, highlighting its needle-free delivery using a nasal spray with an absorption enhancer that ensures effective, safe drug uptake comparable to injections—even under nasal congestion—offering a promising alternative to traditional epinephrine autoinjectors.
Bridging the Gaps in Treatment and Education of Epinephrine
July 7th 2025A panelist discusses how intranasal epinephrine represents a significant advance over traditional autoinjectors by eliminating needles, addressing user anxiety and real-world barriers, and potentially improving adherence and timely treatment in anaphylaxis emergencies.
Needles, Nerves, and Knowledge: What Causes Delay to Epinephrine Treatment
July 7th 2025A panelist discusses how barriers such as cost, fear of injections, and lack of confidence delay epinephrine use in anaphylaxis and explains how intranasal delivery and updated guidelines may reduce hesitation and improve timely, effective treatment through better education and accessibility.
Epinephrine First: The Gold Standard in Anaphylaxis Treatment
July 7th 2025A panelist discusses the critical importance of early epinephrine administration in anaphylaxis for preventing severe outcomes, explaining its multireceptor action and lifesaving potential, while highlighting how intranasal delivery could enhance timely use and empower caregivers with faster, more accessible treatment options.
An Overview of Anaphylaxis and the Importance of Speedy Delivery
July 7th 2025A panelist discusses how intranasal epinephrine could transform anaphylaxis management by improving accessibility, reducing treatment delays, and addressing underuse of epinephrine—especially in pediatric and high-risk populations—while emphasizing the need for better education and more user-friendly interventions to improve outcomes.
An Overview of Coding and Billing With AI Skin Check Tools
July 7th 2025Panelists discuss billing and coding procedures for skin scanning devices, focusing on the use of unlisted Current Procedural Terminology (CPT) 99 codes with proper documentation and modifiers, the importance of clear communication with billing teams, available educational resources to aid primary care settings, and operational considerations including scope-of-practice variations for device use among clinical staff.
Real-World Impact: Patient Case Examples of AI Skin Checks
July 7th 2025Panelists discuss an interactive case session emphasizing the nuanced evaluation of suspicious skin lesions, highlighting tools such as the DermaSensor for risk scoring, the ugly duckling concept, and the importance of combining clinical judgment with technology to guide biopsy decisions and patient follow-up across diverse skin types.
Turning Images Into Action: Identifying Suspicious Lesions With Confidence
July 7th 2025Panelists discuss that decisions to forgo biopsy often weigh patient risk and lesion characteristics with noninvasive tools offering valuable reassurance; while familiarity with artificial intelligence (AI) aids varies, these technologies—used judiciously and alongside clinical expertise—can boost diagnostic confidence, though limitations and integration challenges remain.
Engaging Patients and Embracing New Tools: Communication, Education, and Implementation
July 7th 2025Panelists discuss that successful adoption of artificial intelligence (AI) skin cancer detection tools requires proven effectiveness, easy integration into clinical workflows, appropriate reimbursement, and use as supportive aids that complement—not replace—clinical judgment.
Routine Visits, Real Impact: Where Skin Cancer Checks Fit In
July 7th 2025Panelists discuss how visual examination remains the primary method for evaluating suspicious skin lesions in everyday practice, emphasizing clinical judgment, patient-reported changes, and the growing—but still limited—role of artificial intelligence (AI) tools, while underscoring the importance of vigilance, especially in high-risk and underserved populations with limited access to dermatology.
Integrating AI in Practice: The Future of Skin Checks
July 7th 2025Panelists discuss the challenges of skin cancer evaluations, highlighting patient fears, systemic access barriers, and provider concerns about overreferral, while emphasizing the importance of clear communication, responsible resource use, and cautious adoption of emerging tools such as artificial intelligence (AI), with clinical judgment and trusted educational resources remaining central to care.
Barriers to Care: What Prevents Patients From Seeing a Dermatologist
July 7th 2025Panelists discuss the anxieties primary care providers face in skin cancer evaluation—particularly the fear of missing a malignancy—while highlighting challenges such as limited diagnostic confidence, delayed dermatology access, and disparities in underserved areas, emphasizing the need for better tools and support to empower frontline clinicians and improve early detection.
The Evolving Landscape: Integrating Skin Cancer Screening Into Primary Care
June 26th 2025Panelists discuss the vital role of primary care providers in early skin cancer detection, highlighting the need for improved diagnostic confidence, integration of artificial intelligence (AI) tools, and efficient workflows to overcome time and resource constraints, ultimately aiming to reduce delays and improve patient outcomes.
A Visible Disease with Invisible Pain: Mona Shahriari Discusses Suicide Risk in Atopic Dermatitis
June 25th 2025Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.
Johann Gudjonsson, MD, PhD, on Emerging AD Therapies: From Single Targets to Combination Approaches
June 19th 2025RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.